Announcement • Jan 30
Genomma Lab Internacional, S.A.B. de C.V. to Report Q4, 2025 Results on Feb 25, 2026 Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q4, 2025 results After-Market on Feb 25, 2026 Announcement • Dec 09
Genomma Lab Internacional Announces Fourteenth Dividend Payment, Payable on December 23, 2025 Genomma Lab Internacional, S.A.B. de C.V. informs that the Company presented a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of $0.200000 Mexican pesos per share on its common stock representing a total amount of $200,000,000.00 M.N. (two hundred million pesos 00/100 National Currency), payable to shareholders of record of the applicable circulating shares at the close of business on December 23, 2025. This amount per share is based on the total LABB shares currently outstanding. Announcement • Oct 09
Genomma Lab Internacional, S.A.B. de C.V. to Report Q3, 2025 Results on Oct 22, 2025 Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q3, 2025 results After-Market on Oct 22, 2025 Announcement • Jun 30
Genomma Lab Internacional, S.A.B. de C.V. to Report Q2, 2025 Results on Jul 23, 2025 Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q2, 2025 results After-Market on Jul 23, 2025 Announcement • Jun 24
Genomma Lab Internacional, S.A.B. De C.V. Announces Twelfth Quarterly Dividend Payment, Payable on July 1, 2025 Genomma Lab Internacional, S.A.B. de C.V. informs that the Company filed a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of $0.200000 Mexican pesos per share on its common stock representing a total amount of $200,000,000.00 M.N. (two hundred million pesos 00/100 National Currency), payable to shareholders of record of the applicable circulating shares at the close of business on July 1st, 2025. This amount per share is based on the total LABB shares currently outstanding. Subject to the terms and conditions established by the AGSM, the Company has the intention to make dividend payments on a Quarterly basis. Announcement • Apr 08
Genomma Lab Internacional, S.A.B. de C.V., Annual General Meeting, Apr 24, 2025 Genomma Lab Internacional, S.A.B. de C.V., Annual General Meeting, Apr 24, 2025. Location: antonio dovali jaime no 70, tower c 2nd floor, santa fe neighborhood, cp 01210, mexico Mexico Announcement • Apr 01
Genomma Lab Internacional, S.A.B. de C.V. to Report Q1, 2025 Results on Apr 30, 2025 Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q1, 2025 results After-Market on Apr 30, 2025 Announcement • Mar 07
Genomma Lab Internacional Announces Eleventh Cash Dividend Payment Genomma Lab Internacional, S.A.B. de C.V. informed that the Company filed a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of $0.200000 Mexican pesos per share on its common stock representing a total amount of $200,000,000.00 M.N. (two hundred million pesos 00/100 National Currency), payable to shareholders of record of the applicable circulating shares at the close of business on March 14, 2025. This amount per share is based on the total LABB shares currently outstanding. Genomma's Board of Directors, exercising the powers delegated at the Annual General Shareholders Meeting held on April 30, 2024 ("AGSM"), have therefore deemed it appropriate to make this announced dividend payment. Subject to the terms and conditions established by the AGSM, the Company has the intention to make dividend payments on a Quarterly basis. Announcement • Feb 11
Genomma Lab Internacional, S.A.B. de C.V. to Report Q4, 2024 Results on Feb 26, 2025 Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q4, 2024 results at 3:00 PM, Central Standard Time on Feb 26, 2025 Reported Earnings • Oct 24
Third quarter 2024 earnings released: EPS: Mex$0.70 (vs Mex$0.39 in 3Q 2023) Third quarter 2024 results: EPS: Mex$0.70 (up from Mex$0.39 in 3Q 2023). Revenue: Mex$5.09b (up 16% from 3Q 2023). Net income: Mex$660.1m (up 78% from 3Q 2023). Profit margin: 13% (up from 8.4% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 10% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Oct 05
Genomma Lab Internacional, S.A.B. de C.V. to Report Q3, 2024 Results on Oct 23, 2024 Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q3, 2024 results After-Market on Oct 23, 2024 Announcement • Oct 03
Genomma Lab Pharma Manufacturing Facility Receives Pending GMP Certification for the Mexican Market from the Mexican Ministry of Health's Federal Committee Genomma Lab Internacional, S.A.B. de C.V. announced that it has received Good Manufacturing Practices ("GMP") certification from the Mexican Ministry of Health's Federal Committee for Protection from Sanitary Risks for its oral liquid, topical liquid and tablet coating manufacturing production at Genomma Lab's Medicinas y Medicamentos Nacionales, S.A. de C.V. manufacturing facility in the State of Mexico. Buy Or Sell Opportunity • Aug 23
Now 23% undervalued after recent price drop Over the last 90 days, the stock has fallen 3.8% to €0.88. The fair value is estimated to be €1.14, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.3% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 5.9% per annum. Earnings are also forecast to grow by 19% per annum over the same time period. Reported Earnings • Jul 26
Second quarter 2024 earnings released: EPS: Mex$0.67 (vs Mex$0.43 in 2Q 2023) Second quarter 2024 results: EPS: Mex$0.67 (up from Mex$0.43 in 2Q 2023). Revenue: Mex$4.65b (up 6.4% from 2Q 2023). Net income: Mex$631.6m (up 51% from 2Q 2023). Profit margin: 14% (up from 9.6% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has remained flat. Announcement • Jul 04
Genomma Lab Internacional, S.A.B. de C.V. to Report Q2, 2024 Results on Jul 24, 2024 Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q2, 2024 results After-Market on Jul 24, 2024 Announcement • Jun 16
Genomma Lab Internacional, S.A.B. De C.V. Declares Cash Dividend Genomma Lab Internacional, S.A.B. de C.V. informs that the Company filed a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of $0.200000 Mexican pesos per share on its common stock representing a total amount of $200,000,000.00 M.N., payable to shareholders of record of the applicable circulating shares at the close of business on June 21, 2024. This amount per share is based on the total LABB shares currently outstanding. Genomma's Board of Directors, exercising the powers delegated at the Annual General Shareholders Meeting held on April 30, 2024, have therefore deemed it appropriate to make this announced dividend payment. New Risk • Jun 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (54% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.2% average weekly change). Reported Earnings • Apr 26
First quarter 2024 earnings released First quarter 2024 results: Revenue: Mex$4.20b (flat on 1Q 2023). Net income: Mex$372.1m (up 3.9% from 1Q 2023). Profit margin: 8.9% (up from 8.6% in 1Q 2023). Revenue is forecast to grow 8.0% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Announcement • Apr 05
Genomma Lab Internacional, S.A.B. de C.V. to Report Q1, 2024 Results on Apr 24, 2024 Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q1, 2024 results After-Market on Apr 24, 2024 Announcement • Mar 14
Genomma Lab Internacional, S.A.B. De C.V. Declares Cash Dividend Genomma Lab Internacional, S.A.B. de C.V. informed that the Company filed a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of MXN 0.196080 per share on its common stock representing a total amount of MXN 200,001,600.00 payable to shareholders of record of the applicable circulating shares at the close of business on March 25, 2024. This amount per share is based on the total LABB shares currently outstanding. Genomma's Board of Directors, exercising the powers delegated at the Annual General Shareholders Meeting held on April 28, 2023 (AGSM), have therefore deemed it appropriate to make this seventh announced dividend payment. Reported Earnings • Feb 23
Full year 2023 earnings released: EPS: Mex$1.08 (vs Mex$1.40 in FY 2022) Full year 2023 results: EPS: Mex$1.08 (down from Mex$1.40 in FY 2022). Revenue: Mex$16.5b (down 2.1% from FY 2022). Net income: Mex$1.03b (down 26% from FY 2022). Profit margin: 6.3% (down from 8.3% in FY 2022). Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 7% per year, which means it is performing significantly worse than earnings. Announcement • Jan 24
Genomma Lab Internacional, S.A.B. de C.V. to Report Q4, 2023 Results on Feb 21, 2024 Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q4, 2023 results After-Market on Feb 21, 2024 Announcement • Dec 14
Genomma Lab Internacional, S.A.B. De C.V. Announces Sixth Dividend Payment Genomma Lab Internacional, S.A.B. de C.V. (Genomma Lab) informed that the Company filed a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of MXN 0.196080 per share on its common stock representing a total amount of MXN 200,001,600.00, payable to shareholders of record of the applicable circulating shares at the close of business on December 27, 2023. Reported Earnings • Oct 27
Third quarter 2023 earnings released: EPS: Mex$0.39 (vs Mex$0.40 in 3Q 2022) Third quarter 2023 results: EPS: Mex$0.39 (down from Mex$0.40 in 3Q 2022). Revenue: Mex$4.39b (up 1.0% from 3Q 2022). Net income: Mex$370.7m (down 7.2% from 3Q 2022). Profit margin: 8.4% (down from 9.2% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Announcement • Oct 05
Genomma Lab Internacional, S.A.B. de C.V. to Report Q3, 2023 Results on Oct 25, 2023 Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q3, 2023 results After-Market on Oct 25, 2023 Reported Earnings • Jul 28
Second quarter 2023 earnings released: EPS: Mex$0.43 (vs Mex$0.40 in 2Q 2022) Second quarter 2023 results: EPS: Mex$0.43 (up from Mex$0.40 in 2Q 2022). Revenue: Mex$4.37b (up 1.1% from 2Q 2022). Net income: Mex$417.4m (up 3.1% from 2Q 2022). Profit margin: 9.6% (in line with 2Q 2022). Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 2.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Announcement • Jul 06
Genomma Lab Internacional, S.A.B. de C.V. to Report Q2, 2023 Results on Jul 26, 2023 Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q2, 2023 results After-Market on Jul 26, 2023 Reported Earnings • Apr 28
First quarter 2023 earnings released First quarter 2023 results: Revenue: Mex$4.18b (up 4.1% from 1Q 2022). Net income: Mex$358.0m (up 5.5% from 1Q 2022). Profit margin: 8.6% (up from 8.4% in 1Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.9% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Reported Earnings • Feb 24
Full year 2022 earnings released: EPS: Mex$1.40 (vs Mex$1.30 in FY 2021) Full year 2022 results: EPS: Mex$1.40 (up from Mex$1.30 in FY 2021). Revenue: Mex$16.9b (up 8.9% from FY 2021). Net income: Mex$1.40b (up 6.8% from FY 2021). Profit margin: 8.3% (down from 8.4% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.9% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Announcement • Jan 31
Genomma Lab Internacional, S.A.B. de C.V. to Report Q4, 2022 Results on Feb 22, 2023 Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q4, 2022 results After-Market on Feb 22, 2023 Board Change • Nov 16
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 4 highly experienced directors. Independent Proprietary Board Member Marco Francisco Forastieri Muñoz was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Upcoming Dividend • Nov 02
Upcoming dividend of Mex$0.38 per share Eligible shareholders must have bought the stock before 09 November 2022. Payment date: 11 November 2022. Payout ratio is a comfortable 29% and this is well supported by cash flows. Trailing yield: 2.4%. Lower than top quartile of German dividend payers (5.1%). Lower than average of industry peers (2.8%). Reported Earnings • Oct 28
Third quarter 2022 earnings released: EPS: Mex$0.40 (vs Mex$0.39 in 3Q 2021) Third quarter 2022 results: EPS: Mex$0.40 (up from Mex$0.39 in 3Q 2021). Revenue: Mex$4.35b (up 9.2% from 3Q 2021). Net income: Mex$399.3m (up 1.5% from 3Q 2021). Profit margin: 9.2% (in line with 3Q 2021). Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Announcement • Oct 27
Genomma Lab Internacional, S.A.B. De C.V. Cash Dividend Genomma LabInternacional, S.A.B. de C.V. declaring a cash dividend of MXN 0.381679389 per share on its common stock representing a total amount of $400,000,000.00 M.N. (four hundred million pesos 00/100 National Currency), payable to shareholders of record at the close of business on November 11, 2022. This amount is based on the total LABB shares currently in circulation. Announcement • Oct 18
Genomma Lab Internacional, S.A.B. de C.V. to Report Q3, 2022 Results on Oct 26, 2022 Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q3, 2022 results After-Market on Oct 26, 2022 Reported Earnings • Jul 29
Second quarter 2022 earnings released: EPS: Mex$0.40 (vs Mex$0.38 in 2Q 2021) Second quarter 2022 results: EPS: Mex$0.40 (up from Mex$0.38 in 2Q 2021). Revenue: Mex$4.32b (up 12% from 2Q 2021). Net income: Mex$404.7m (up 6.7% from 2Q 2021). Profit margin: 9.4% (in line with 2Q 2021). Over the next year, revenue is forecast to grow 1.9%, compared to a 8.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Announcement • Jul 13
Genomma Lab Internacional, S.A.B. de C.V. to Report Q2, 2022 Results on Jul 27, 2022 Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q2, 2022 results After-Market on Jul 27, 2022 Announcement • Jun 01
Genomma Lab Internacional, S.A.B. de C.V. Declares Second Cash Dividend Payment Genomma Lab Internacional, S.A.B. de C.V. declaring a cash dividend on its common stock of MXN 0.381679389 per share, or a total amount of MXN 400,000,000.00, payable to shareholders of record at the close of business on June 2, 2022. This amount represents the total LABB shares currently in circulation This payment is in addition to the prior dividend paid on December 10, 2021 and therefore represents the total dividend approved at the Company's Ordinary and Extraordinary Annual General Shareholders Meeting held on April 27, 2017 which delegated to the Board of Directors the faculty to determine the payment dates of said dividends. Reported Earnings • Apr 30
First quarter 2022 earnings released First quarter 2022 results: Revenue: Mex$4.01b (up 13% from 1Q 2021). Net income: Mex$339.2m (up 6.2% from 1Q 2021). Profit margin: 8.4% (down from 9.0% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 6.2%, compared to a 8.1% growth forecast for the industry in Germany. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. Independent Director Carlos Javier Vara Alonso was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Announcement • Apr 20
Genomma Lab Internacional, S.A.B. de C.V. to Report Q1, 2022 Results on Apr 27, 2022 Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q1, 2022 results After-Market on Apr 27, 2022 Reported Earnings • Feb 24
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Full year 2021 results: EPS: Mex$1.44 (down from Mex$1.45 in FY 2020). Revenue: Mex$15.5b (up 12% from FY 2020). Net income: Mex$1.45b (down 1.3% from FY 2020). Profit margin: 9.4% (down from 11% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 4.3%. Over the next year, revenue is forecast to grow 5.8%, compared to a 7.7% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 19% per year whereas the company’s share price has increased by 14% per year. Announcement • Feb 02
Genomma Lab Internacional, S.A.B. de C.V. to Report Q4, 2021 Results on Feb 23, 2022 Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q4, 2021 results After-Market on Feb 23, 2022 Valuation Update With 7 Day Price Move • Dec 30
Investor sentiment improved over the past week After last week's 16% share price gain to €1.04, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 21x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 99% over the past three years. Reported Earnings • Oct 29
Third quarter 2021 earnings released: EPS Mex$0.39 (vs Mex$0.40 in 3Q 2020) The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: Mex$3.98b (up 16% from 3Q 2020). Net income: Mex$393.2m (down 3.9% from 3Q 2020). Profit margin: 9.9% (down from 12% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 12% per year. Reported Earnings • Jul 30
Second quarter 2021 earnings released: EPS Mex$0.38 (vs Mex$0.36 in 2Q 2020) The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2021 results: Revenue: Mex$3.87b (up 6.3% from 2Q 2020). Net income: Mex$379.2m (up 5.1% from 2Q 2020). Profit margin: 9.8% (in line with 2Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 9% per year. Reported Earnings • May 02
First quarter 2021 earnings released: EPS Mex$0.32 (vs Mex$0.37 in 1Q 2020) The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2021 results: Revenue: Mex$3.55b (up 6.4% from 1Q 2020). Net income: Mex$319.4m (down 14% from 1Q 2020). Profit margin: 9.0% (down from 11% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 4% per year. Is New 90 Day High Low • Feb 16
New 90-day high: €0.91 The company is up 21% from its price of €0.76 on 18 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 14% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.07 per share. Announcement • Feb 05
Genomma Lab Internacional, S.A.B. de C.V. to Report Q4, 2020 Results on Feb 24, 2021 Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q4, 2020 results After-Market on Feb 24, 2021 Is New 90 Day High Low • Jan 20
New 90-day high: €0.86 The company is up 2.0% from its price of €0.84 on 22 October 2020. The German market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 22% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.95 per share. Is New 90 Day High Low • Dec 22
New 90-day low: €0.75 The company is down 10.0% from its price of €0.83 on 23 September 2020. The German market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.81 per share. Is New 90 Day High Low • Oct 30
New 90-day low: €0.76 The company is down 14% from its price of €0.89 on 31 July 2020. The German market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.63 per share. Reported Earnings • Oct 24
Third quarter earnings released Over the last 12 months the company has reported total profits of Mex$1.18b, up 26% from the prior year. Total revenue was Mex$13.6b over the last 12 months, up 7.9% from the prior year. Analyst Estimate Surprise Post Earnings • Oct 24
Third-quarter earnings released: Revenue beats expectations Third-quarter revenue exceeded analyst estimates by 3.0% at Mex$3.43b. Revenue is forecast to grow 9.3% over the next year, compared to a 2.6% growth forecast for the Pharmaceuticals industry in Germany. Reported Earnings • Oct 22
Third quarter earnings released Over the last 12 months the company has reported total profits of Mex$1.18b, up 26% from the prior year. Total revenue was Mex$13.6b over the last 12 months, up 7.9% from the prior year. Announcement • Oct 14
Genomma Lab Internacional, S.A.B. de C.V. to Report Q3, 2020 Results on Oct 21, 2020 Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q3, 2020 results at 5:00 PM, Central Standard Time (Mexico) on Oct 21, 2020 Announcement • Oct 03
Genomma Lab Internacional, S.A.B. de C.V. to Report Q2, 2019 Results on Jul 24, 2019 Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q2, 2019 results at 5:00 PM, Central Standard Time (Mexico) on Jul 24, 2019 Announcement • Jul 17
Genomma Lab Internacional, S.A.B. de C.V. to Report Q2, 2020 Results on Jul 22, 2020 Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q2, 2020 results at 5:00 PM, Central Standard Time (Mexico) on Jul 22, 2020 
